Posaconazole
ApprovedWithdrawn 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Clinical Infection
Conditions
Clinical Infection
Trial Timeline
Dec 1, 2013 → —
NCT ID
NCT02020213About Posaconazole
Posaconazole is a approved stage product being developed by Merck for Clinical Infection. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02020213. Target conditions include Clinical Infection.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00686621 | Pre-clinical | Completed |
| NCT05065658 | Pre-clinical | Completed |
| NCT03318159 | Phase 2 | Completed |
| NCT03336502 | Phase 1 | Completed |
| NCT02387983 | Phase 1 | Completed |
| NCT02020213 | Approved | Withdrawn |
| NCT00811642 | Phase 3 | Completed |
| NCT00686543 | Approved | Completed |
| NCT00550732 | Phase 2 | Completed |
| NCT00726609 | Pre-clinical | Completed |
| NCT00034658 | Phase 3 | Completed |
Competing Products
20 competing products in Clinical Infection